US FDA Approved First Gene Therapy to Treat Hemophilia B
CSL, a global biotechnology leader announced that the US Food and Drug Administration (FDA) approved HEMGENIX, the first one-time gene therapy to treat patients with hemophilia B. HEMGENIX is used to treat adults with hemophilia B who currently use factor IX prophylaxis therapy or have life-threatening haemorrhages. In the clinical trial,
Read More